A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Neurology

Volumn 73, Issue 22, 2009, Pages 1914-1922

  Teunissen, C E ^a   Petzold, A ^b   Bennett, J L ^c   Berven, F S ^d   Brundin, L ^e   Comabella, M ^f   Franciotta, D ^g   Frederiksen, J L ^h   Fleming, J O ⁱ   Furlan, R ^j   Hintzen, R Q ^k   Hughes, S G ^l   Johnson, M H ^m   Krasulova, E ⁿ   Kuhle, J ^o   Magnone, M C ^p   Rajda, C ^q   Rejdak, K ^r   Schmidt, H K ^s   Van Pesch, V ^t   Waubant, E ^u   Wolf, C ^v   Giovannoni, G ^w   Hemmer, B ^x   Tumani, H ^y   Deisenhammer, F ^z   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l Medical Research   (United Kingdom)

^m LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p F HOFFMANN LA ROCHE LTD   (Switzerland)

^q UNIVERSITY OF SZEGED   (Hungary)

^r MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^s Accelerated Cure Project for Multiple Sclerosis   (United States)

^t CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UCB PHARMA   (Belgium)

^w QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^x TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^y UNIVERSITY HOSPITAL ULM   (Germany)

^z INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; PROPYLENE; PROTEIN;

BLOOD SAMPLING; CELL COUNT; CEREBROSPINAL FLUID; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSENSUS; COOLING; ERYTHROCYTE; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; FREEZING; FUNCTIONAL ASSESSMENT; HUMAN; LOW TEMPERATURE; LUMBAR PUNCTURE; MEDICAL ETHICS; MULTIPLE SCLEROSIS; NEEDLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT INFORMATION; PLASMA; PRACTICE GUIDELINE; PRESERVATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REVIEW; ROOM TEMPERATURE; STANDARDIZATION; STORAGE TEMPERATURE; TUBE; VERTEBRA BODY; ARTICLE; BIBLIOGRAPHIC DATABASE; DISABILITY; HEALTH CARE FACILITY; HOSPITALIZATION; LABORATORY DIAGNOSIS; METHODOLOGY; PATHOLOGY; STANDARD; STATISTICS; UNITED KINGDOM;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; CONSENSUS; DATABASES, BIBLIOGRAPHIC; DISABILITY EVALUATION; ENGLAND; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; SPECIMEN HANDLING;

EID: 73349120602     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c47cc2     Document Type: Review

References (49)

1. Deisenhammer F, Bartos A, Egg R, et al. Guidelines on routine cerebrospinal fluid analysis: report from an EFNS task force. Eur J Neurol 2006;13:913-922.
2. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127:1463-1478.
3. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurology 2005;4:32-41.
4. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 2006;44:750-759. (Pubitemid 43832871)
5. Reiber H. Dynamics of brain-derived proteins in cerebro-spinal fluid. Clin Chim Acta 2001;310:173-186.
6. Martino G, Grimaldi LM, Moiola L, et al. Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. J Neuroimmunol 1990; 30:129-134.
7. Grant R, Condon B, Hart I, Teasdale GM. Changes in intracranial CSF volume after lumbar puncture and their relationship to post-LP headache. J Neurol Neurosurg Psychiatry 1991;54:440-442.
8. Kuntz KM, Kokmen E, Stevens JC, Miller P, Offord KP, Ho MM. Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology 1992;42:1884-1887.
9. Thompson EJ. The CSF Proteins: A Biochemical Approach. Amsterdam: Elsevier; 2005.
10. Petzold A, Sharpe LT, Keir G. Spectrophotometry for ce-rebrospinal fluid pigment analysis. Neurocrit Care 2006;4: 153-162.
11. Berven FS, Kroksveen AC, Berle M, et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 2007;1:699-711.
12. Jimenez CR, Koel-Simmelink MJR, Pham T, Voort van der L, Teunissen CE. Endogenous peptide profiling of ce-rebrospinal fluid by MALDI-TOF mass spectrometry. Proteomics Clin Appl 2007;1:1385-1392.
13. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220-225.
14. Carson D, Serpell M. Choosing the best needle for diagnostic lumbar puncture. Neurology 1996;47:33-37.
15. Lewczuk P, Beck G, Esselmann H, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 2006; 52:332-334.
16. Murillo-Rodriguez E, Desarnaud F, Prospero-Garcia O. Diurnal variation of arachidonoylethanolamine, palmi-toylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 2006;79:30-37.
17. Jimenez CR, Piersma S, Pham TV. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. Biomark Med 2007;1:541-565.
18. Scharbert G, Kalb M, Marschalek C, Kozek-Langenecker SA. The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg 2006;102:1280-1284.
19. Lomholt AF, Frederiksen CB, Christensen IJ, Brunner N, Nielsen HJ. Plasma tissue inhibitor of metall-oproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 2007;380:128-132.
20. West-Nielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NH. Sample handling for mass spec-trometric proteomic investigations of human sera. Anal Chem 2005;77:5114-5123.
21. Kenis G, Teunissen C, De JR, Bosmans E, Steinbusch H, Maes M. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine 2002;19:228-235.
22. Chaigneau C, Cabioch T, Beaumont K, Betsou F. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 2007;45:1390-1395.
23. Schoonenboom NS, Mulder C, Vanderstichele H, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005; 51:189-195.
24. Bibl M, Esselmann H, Otto M, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004;25:2912-2918.
25. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Pro-teome Res 2009;8:113-117.
26. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez JC. Truncated cystatin C in cerebrospinal fluid: technical [corrected] artefact or biological process? Proteomics 2005;5:3060-3065.
27. Triendl A. The clinical significance of monoclonal and bi-clonal bands in cerebrospinal fluid isoelectric focusing. Available at: http://aleph.uibk.ac. at/ALEPH/-/F?func=find-b&request=AC03081400&find-code=WID 2000. Accessed October 8, 2009.
28. Garton MJ, Keir G, Lakshmi MV, Thompson EJ. Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci 1991;104:74-80.
29. Moulds JM. Ethnic diversity of class III genes in autoimmune disease. Front Biosci 2001;6:D986-D991.
30. Rinker JR, Trinkaus K, Naismith RT, Cross AH. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology 2007;69:68-72.
31. National Institutes of Health. NIH policy on reporting race and ethnicity data: subjects in clinical research. Available at: http://grants.nih.gov/ grants/guide/notice-files/ NOT-OD-01-053.html. Released August 8, 2001. Accessed October 8, 2009.
32. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
33. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846.
34. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
36. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
37. Barkhof F. MRI in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS). Mult Scler 1999;5: 283-286.
38. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(pt 5):871-882.
39. http://www.nationalmssociety.org/for-professionals/researchers/ clinical-study-measures/msfc/index.aspx. Accessed October 8, 2009.
40. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283-288.
41. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-568.
42. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007;20:286-293.
43. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
44. Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 1992; 86:291-297.
45. Rieckmann P, Altenhofen B, Riegel A, Kallmann B, Fel-genhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Mult Scler 1998;4:178-182.
46. Andersson M, Varez-Cermeno J, Bernardi G, et al. Cere-brospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57: 897-902.
47. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-870.
48. Jasperse B, Valsasina P, Neacsu V, et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging 2007;26:881-885.
49. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6:677-686.